J&J Slaps Samsung Bioepis With Stelara Lawsuit In US
As Pyzchiva Biosimilar Launches, Originator Says PBM Deal Breaches Settlement
The same day as Samsung Bioepis and Sandoz launched their partnered Pyzchiva biosimilar rival to Stelara in the US, originator J&J hit the Korean developer with a lawsuit claiming that a private-label commercialization deal with a US pharmacy benefit manager violates the ustekinumab settlement that allowed the firms to launch.
